China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu,… Read more
China SXT Pharmaceuticals Inc (SXTC) - Total Assets
Latest total assets as of September 2025: $26.35 Million USD
Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) holds total assets worth $26.35 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
China SXT Pharmaceuticals Inc - Total Assets Trend (2016–2025)
This chart illustrates how China SXT Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
China SXT Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
China SXT Pharmaceuticals Inc's total assets of $26.35 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.6% |
| Accounts Receivable | $1.90 Million | 8.8% |
| Inventory | $828.05K | 3.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $11.81K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how China SXT Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China SXT Pharmaceuticals Inc's current assets represent 98.3% of total assets in 2025, an increase from 91.1% in 2016.
- Cash Position: Cash and equivalents constituted 83.6% of total assets in 2025, up from 0.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 8.8% of total assets.
China SXT Pharmaceuticals Inc Competitors by Total Assets
Key competitors of China SXT Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
China SXT Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - China SXT Pharmaceuticals Inc generates 0.08x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - China SXT Pharmaceuticals Inc is currently not profitable relative to its asset base.
China SXT Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.37 | 1.40 | 4.01 |
| Quick Ratio | 4.24 | 1.30 | 3.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $20.08 Million | $ 6.32 Million | $ 16.55 Million |
China SXT Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between China SXT Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.09 |
| Latest Market Cap to Assets Ratio | 0.05 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | $21.66 Million |
| Market Capitalization | $984.69K USD |
Valuation Analysis
Below Book Valuation: The market values China SXT Pharmaceuticals Inc's assets below their book value (0.05 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: China SXT Pharmaceuticals Inc's assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for China SXT Pharmaceuticals Inc (2016–2025)
The table below shows the annual total assets of China SXT Pharmaceuticals Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $21.66 Million | -6.33% |
| 2024-03-31 | $23.13 Million | -21.75% |
| 2023-03-31 | $29.55 Million | -11.90% |
| 2022-03-31 | $33.55 Million | -2.90% |
| 2021-03-31 | $34.55 Million | +59.19% |
| 2020-03-31 | $21.70 Million | +24.22% |
| 2019-03-31 | $17.47 Million | +128.14% |
| 2018-03-31 | $7.66 Million | +40.99% |
| 2017-03-31 | $5.43 Million | -13.75% |
| 2016-03-31 | $6.30 Million | -- |